Clinical Trials
4 trialsNCT06532279 2026-05-04
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT02508389 2021-09-20
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed